Federal Register / Vol. 76, No. 250 / Thursday, December 29, 2011 / Notices 81945 

Exhibit 2 shows the estimated 

annualized cost burden associated with 

respondents’ time to participate in this 

research. The total cost burden is 

estimated to be $37,363 annually. 

EXHIBIT 1—ESTIMATED ANNUALIZED BURDEN HOURS

Activity Number of 

respondents 

Number of 

responses per 

respondent 

Hours per 

response 

Total burden 

hours 

MEPS Cancer SAQ ......................................................................................... 3,500 1 30/60 1750 

Total .......................................................................................................... 3,500 n/a n/a 1750 

EXHIBIT 2—ESTIMATED ANNUALIZED COST BURDEN

Activity Number of 

respondents 

Total burden 

hours 

Average 

hourly wage 

rate* 

Total cost 

burden hours 

MEPS Cancer SAQ ......................................................................................... 3,500 1,750 $21.35 $37,363 

Total .......................................................................................................... 3,500 1,750 n/a 37,363 

* Based on the mean average hourly rate for all occupations (00–0000), National Compensation Survey: Occupational Wages in the United 

States May 2010, ‘‘U.S. Department of labor, Bureau of Labor Statistics’’. 

Estimated Annual Costs to the Federal 

Government 

Exhibit 3 shows the estimated total 

cost for the Cancer SAQ. Since the SAQ 

will only be used once in 2012 the total 

and annual costs are identical. The total 

cost is approximately $1,050,000. 

EXHIBIT 3—ESTIMATED TOTAL AND ANNUALIZED COST

Cost component Total cost Annualized 

cost 

Sampling Activities ................................................................................................................................................... $20,000 $20,000 

Interviewer Recruitment and Training ..................................................................................................................... 0 0 

Data Collection Activities ......................................................................................................................................... 300,000 300,000 

Data Processing ...................................................................................................................................................... 600,000 600,000 

Production of Public Use Data Files ....................................................................................................................... 80,000 80,000 

Project Management ................................................................................................................................................ 50,000 50,000 

Total .................................................................................................................................................................. 1,050,000 1,050,000 

Request for Comments 

In accordance with the Paperwork 

Reduction Act, comments on AHRQ’s 

information collection are requested 

with regard to any of the following: (a) 

Whether the proposed collection of 

information is necessary for the proper 

performance of AHRQ healthcare 

research and healthcare information 

dissemination functions, including 

whether the information will have 

practical utility; (b) the accuracy of 

AHRQ’s estimate of burden (including 

hours and costs) of the proposed 

collection(s) of information; (c) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(d) ways to minimize the burden of the 

collection of information upon the 

respondents, including the use of 

automated collection techniques or 

other forms of information technology. 

Comments submitted in response to 

this notice will be summarized and 

included in the Agency’s subsequent 

request for OMB approval of the 

proposed information collection. All 

comments will become a matter of 

public record. 

Dated: December 21, 2011. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 2011–33293 Filed 12–28–11; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality 

Request for Measures and Domains To 

Use in Development of a Standardized 

Instrument for Use in Public Reporting 

of Family Experience of Pediatric 

Inpatient Care 

AGENCY: Agency for Healthcare Research 

and Quality (AHRQ), HHS. 

ACTION: Notice of request for measures 

and domains. 

SUMMARY: Section 401(a) of the 

Children’s Health Insurance Program 

Reauthorization Act of 2009 (CHIPRA), 

Public Law 111–3, amended the Social 

Security Act (the Act) to enact section 

1139A (42 U.S.C. 1320b–9a). Section 

1139A(b) charged the Department of 


wreier-aviles on DSK3TPTVN1PROD with NOTICES
81946 Federal Register / Vol. 76, No. 250 / Thursday, December 29, 2011 / Notices 

Health and Human Services with 

improving pediatric health care quality 

measures. The Agency for Healthcare 

Research and Quality (AHRQ) is 

soliciting the submission of instruments 

or domains (for example, key concepts) 

measuring aspects of families’ 

experience with the quality of inpatient 

medical and surgical hospital care from 

all researchers, vendors, hospitals, 

stakeholders, and other interested 

parties. The survey development team 

of Children’s Hospital Boston Center of 

Excellence for Pediatric Quality 

Measurement (CEPQM), is one of the 

CHIPRA Pediatric Quality Measures 

Program (PQMP) Centers of Excellence, 

which were created pursuant to an 

interagency agreement between the 

Centers for Medicare & Medicaid 

Services (CMS) and AHRQ, and are 

funded through cooperative agreement 

awards with AHRQ. AHRQ is interested 

in instruments and items through which 

families of pediatric patients assess the 

care their child receives during the 

child’s inpatient stay. The goal is to 

develop a standardized instrument for 

use in the public reporting of family 

experience of pediatric inpatient care. 

The team developing this survey 

intends to submit it to the CAHPS 

Consortium to request use of the CAHPS 

trademark. The survey will be 

developed in accordance with CAHPS 

Survey Design Principles and will 

develop implementation instructions 

based on those for CAHPS instruments 

(https://www.cahps.AHRQ.gov/AboutCAHPS/Principles.aspx.) All CAHPS 

surveys are available to users free of 

charge and are published on the AHRQ 

Web site. 

DATES: Please submit materials January 

30, 2012. AHRQ will not respond to 

individual submissions, but will 

consider all suggestions. 

ADDRESSES: Electronic submissions are 

encouraged, preferably as an email with 

an electronic file in a standard word 

processing format as an email 

attachment. Submissions may also be in 

the form of a letter to: Maushami 

DeSoto, MHA, Ph.D., Staff Service 

Fellow, Office of Extramural Research, 

Education and Priority, Populations 

Agency for Healthcare Research and 

Quality, 540 Gaither Rd, Rockville, MD 

20850, Phone: (301) 427–1546, Fax: 

(301) 427–1238, Email: 

Maushami.DesotoAHRQ.hhs.gov. 

All submissions must include a 

written statement from the submitter 

that it will grant AHRQ the necessary 

rights to use, modify, and adapt the 

submitted instruments, items, and their 

documentation for the development of 

this survey and its dissemination for 

AHRQ purposes. In accordance with 

CHIPRA’s charge to improve pediatric 

quality care measures, and consistent 

with AHRQ’s mandate to disseminate 

research results, 42 U.S.C. 299c–3, 

AHRQ purposes include public 

disclosure and dissemination (e.g., on 

the AHRQ Web site) of AHRQ products 

and the results of AHRQ-sponsored 

research and activities. The written 

statement must be signed by an 

individual authorized to act for any 

holder of copyright and/or data rights 

on each submitted measure or 

instrument. The authority of the 

signatory to provide such authorization 

should be described in the letter. 

Submitters must attach a proposed 

license granting all of the abovereferenced rights, including the 

following terms: 

• A worldwide, royalty-free, 

nonexclusive, irrevocable license to 

AHRQ and those acting on its behalf to 

reproduce, prepare derivative works of, 

and otherwise use the submitted 

materials for the development of AHRQ 

products, including a standardized 

instrument for use in the public 

reporting of family experience of 

pediatric inpatient care; and 

• The right of AHRQ and those acting 

on its behalf to publicly disseminate, in 

any media (including AHRQ’s Web site), 

any derivative works that AHRQ or 

those acting on its behalf develops 

based on the submitted materials. 

Submission Guidelines 

When submitting instruments, please 

include, to the extent that it is available: 

• Name of the instrument; 

• Copies of the full instrument, in all 

languages available; 

• Domains or key concepts included 

in the instrument; 

• Instrument reliability (internal 

consistency, test-retest, etc) and validity 

(content, construct, criterion-related); 

• Results of cognitive testing; 

• Results of field-testing; 

• Current use of the instrument (who 

is using it, what it is being used for, how 

instrument findings are reported, and by 

whom the findings are used); and 

• Relevant peer-reviewed journal 

articles or full citations. 

When submitting domains, please 

include, to the extent available: 

• Detailed descriptions of question 

domain and specific purpose; 

• Sample questions, in all languages 

available; and 

• Relevant peer-reviewed journal 

articles or full citations. For all 

submissions, please also include: 

• A brief cover letter summarizing the 

information requested above for 

submitted instruments and domains, 

respectively; 

• Complete information about the 

person submitting the material, 

including: 

(a) Name; 

(b) Title; 

(c) Organization; 

(d) Mailing address; 

(e) Telephone number; 

(f) Email address; and 

(g) The written statement granting 

AHRQ the necessary rights to use, 

modify, and adapt the submitted 

instruments, items, and their supporting 

documentation for the development of 

the survey and its dissemination for 

AHRQ purposes, as described above. 

FOR FURTHER INFORMATION CONTACT: 

Maushami DeSoto, MHA, Ph.D. 

SUPPPLEMENTARY INFORMATION: Section 

401(a) of the Children’s Health 

Insurance Program Reauthorization Act 

of 2009 (CHIPRA), Public Law 111–3, 

amended the Social Security Act (the 

Act) to enact section 1139A (42 U.S.C. 

1320b–9a). Since the law was passed, 

the Agency for Healthcare Research and 

Quality (AHRQ) and the Centers for 

Medicare & Medicaid Services (CMS) 

have been working together to 

implement selected provisions of the 

legislation related to children’s health 

care quality. Section 1139A(b) of the Act 

charged the Department of Health and 

Human Services with improving 

pediatric health care quality measures. 

To implement the law, AHRQ and CMS 

have established the CHIPRA Pediatric 

Quality Measures Program (PQMP), 

which is designed to enhance select 

pediatric quality measures and develop 

new measures as needed. 

The Children’s Hospital Boston 

Center of Excellence for Pediatric 

Quality Measurement (CEPQM) is one of 

seven CHIPRA PQMP Centers of 

Excellence, which were created 

pursuant to an interagency agreement 

between CMS and AHRQ and funded 

through cooperative agreement awards 

with AHRQ. CEPQM has been assigned 

to develop a family experience of 

pediatric inpatient care measure to be 

considered as a standardized instrument 

for publicly reporting pediatric 

inpatient hospital family experiences 

voluntarily by State Medicaid and CHIP 

programs and to be used by providers, 

consumers, other public and private 

purchasers, and others. The team 

developing this survey intends to 

submit it to the CAHPS Consortium to 

request use of the CAHPS trademark. 

Existing instruments or domains 

submitted should capture the family’s 

experience of hospital or related care 

(for example, preparation for discharge 

or care coordination). The survey 

development team is looking for items 


wreier-aviles on DSK3TPTVN1PROD with NOTICES
Federal Register / Vol. 76, No. 250 / Thursday, December 29, 2011 / Notices 81947 

for which families of pediatric 

inpatients are generally the best or only 

judge; for example, the family can best 

say if the provider spent sufficient time 

with them or explained things in ways 

they could understand. Existing 

instruments that have been tested 

should have a high degree of reliability 

and validity; and evidence of wide use 

will be helpful. 

Dated: December 20, 2011. 

Carolyn M. Clancy, 

AHRQ Director. 

[FR Doc. 2011–33290 Filed 12–28–11; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

World Trade Center Health Program 

Scientific/Technical Advisory 

Committee (WTCHP STAC or Advisory 

Committee), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463) the Centers for Disease 

Control and Prevention (CDC), 

announces the following meetings of the 

aforementioned committee: 

COMMITTEE PUBLIC MEETING TIMES AND

DATES: (All times are Eastern Standard 

Time). 

TELECONFERENCE MEETING: 1 p.m.–5 

p.m., January 24, 2012. 

This meeting is available via the USA 

toll-free, dial-in number: 1–(888) 801– 

1939. To be automatically connected to 

the meeting, you will need to enter the 

following participant code: 62062756. 

PUBLIC COMMENT TIMES AND DATE: 

4 p.m.–4:45 p.m., January 24, 2012. 

Please note that the public comment 

period ends at the time indicated or 

following the last call for comments, 

whichever is earlier. Members of the 

public who want to comment must sign 

up by providing their name by mail, 

facsimile, email, or telephone, as given 

below. Each commenter will be 

provided up to five minutes for 

comment. A limited number of time 

slots are available and will be assigned 

on a first come-first served basis. 

Written comments will also be accepted 

from those unable to attend the public 

session. 

Status: Open to the public, limited 

only by the number of telephone lines. 

The conference line will accommodate 

up to 100 callers; therefore it is 

suggested that those interested in calling 

in to listen to the committee meeting 

share a line when possible. 

Background: The Advisory Committee 

was established by Public Law 111–347 

(The James Zadroga 9/11 Health and 

Compensation Act of 2010, Title XXXIII 

of the Public Health Service Act), 

enacted on January 2, 2011 and codified 

at 42 U.S.C. 300mm–300mm–61. 

Purpose: The purpose of the Advisory 

Committee is to review scientific and 

medical evidence and to make 

recommendations to the World Trade 

Center (WTC) Program Administrator 

regarding additional WTC Health 

Program eligibility criteria and potential 

additions to the list of covered WTCrelated health conditions. Title XXXIII 

of the Public Health Service Act 

established within the Department of 

Health and Human Services (HHS), the 

World Trade Center (WTC) Health 

Program, to be administered by the WTC 

Program Administrator. The WTC 

Health Program provides: (1) Medical 

monitoring and treatment benefits to 

eligible emergency responders and 

recovery and cleanup workers 

(including those who are Federal 

employees) who responded to the 

September 11, 2011, terrorist attacks, 

and (2) initial health evaluation, 

monitoring, and treatment benefits to 

residents and other building occupants 

and area workers in New York City who 

were directly impacted and adversely 

affected by such attacks (‘‘survivors’’). 

Certain specific activities of the WTC 

Program Administrator are reserved to 

the Secretary, HHS, to delegate at her 

discretion; other WTC Program 

Administrator duties not explicitly 

reserved to the Secretary, HHS, are 

assigned to the Director, NIOSH. The 

administration of the Advisory 

Committee established under Section 

300mm–1(a) is left to the Director of 

NIOSH in his role as WTC Program 

Administrator. CDC and NIOSH provide 

funding, staffing, and administrative 

support services for the Advisory 

Committee. The charter was issued on 

May 12, 2011, and will expire on May 

12, 2013. 

MATTERS TO BE DISCUSSED: The agenda 

for the Advisory Committee meeting 

includes: WTC Health Program Research 

Priorities and the petition to add cancer 

to the list of WTC Health Program 

covered conditions. The agenda is 

subject to change as priorities dictate. In 

the event an individual cannot attend, 

written comments may be submitted. 

The comments should be limited to two 

pages and submitted to the contact 

person below by January 18, 2012. 

Efforts will be made to provide the twopage written comments received by the 

deadline below to the committee 

members before the meeting. Comments 

in excess of two pages will be made 

publicly available at the NIOSH docket 

(http://www.cdc.gov/niosh/docket/ 

archive/docket248.html). 

PUBLIC COMMENT SIGN-UP AND

SUBMISSIONS TO THE DOCKET: To sign up 

to provide public comments or to 

submit comments to the docket, send 

information to the NIOSH Docket Office 

by one of the following means: 

Mail: NIOSH Docket Office, Robert A. 

Taft Laboratories, MS–C–34, 4676 

Columbia Parkway, Cincinnati, Ohio 

45226. 

Facsimile: (513) 533–8285. 

Email: nioshdocket@cdc.gov. 

Telephone: (513) 533–8611. 

Submissions to the docket should 

reference docket #248. 

Policy on Redaction of Committee 

Meeting Transcripts (Public Comment): 

Transcripts will be prepared and posted 

to NIOSH Docket 248 within 60 days 

after the meeting. If a person making a 

comment gives his or her name, no 

attempt will be made to redact that 

name. NIOSH will take reasonable steps 

to ensure that individuals making 

public comments are aware of the fact 

that their comments (including their 

name, if provided) will appear in a 

transcript of the meeting posted on a 

public Web site. Such reasonable steps 

include: (a) A statement read at the start 

of the meeting stating that transcripts 

will be posted and names of speakers 

will not be redacted; and (b) A printed 

copy of the statement mentioned in (a) 

above will be displayed on the table 

where individuals sign up to make 

public comments. If individuals in 

making a statement reveal personal 

information (e.g., medical information) 

about themselves, that information will 

not usually be redacted. The CDC 

Freedom of Information Act coordinator 

will, however, review such revelations 

in accordance with the Freedom of 

Information Act and if deemed 

appropriate, will redact such 

information. Disclosures of information 

concerning third party medical 

information will be redacted. 

CONTACT PERSON FOR MORE INFORMATION: 

Paul J. Middendorf, Ph.D., Designated 

Federal Official, NIOSH, CDC, 4676 

Columbia Parkway, MailStop R–45, 

Cincinnati, Ohio 45226, Telephone: 1 

(888) 982–4748; email: wtcstac@cdc.gov. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

Notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 


wreier-aviles on DSK3TPTVN1PROD with NOTICES